Qualitative methods for predicting immunotherapy response are available but are technically challenging and subjective. An emerging quantitative predictor of immunotherapy response, tumor mutational burden (TMB), measures the number of somatic mutations per Mb of the genome. TMB calculations using whole exome data have been shown to correlate with patient response to immunotherapies. However, derivation of this score is not well characterized, nor is the score universally performed across laboratories.
In this poster, we describe the ramifications of varying cancer panel sizes and read depths on the calculation of TMB scores. We show impacts of gene content and sequencing depth for providing a range of burden scores that could be used for setting appropriate thresholds for determining therapeutic implications.
Authors: Natalie Mola, Scott Yourstone, Victor Weigman